Noxopharm Limited
NOXOF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$18.74M
Close$
$-0.04
194.4% downside
Current Fair Value
194.4% downsideOvervalued by 194.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $18.74 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.01 |
| Beta | 0.14 |
| Outstanding Shares | 292,237,950 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -3.99 |
|---|---|
| PEG | 14.07 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Noxopharm Limited
8 employees
CEO: Olivier Laczka
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvan...